Herpes simplex virus is the leading cause of blindness due to infectious disease in the United States. Several antivirals are currently approved for treating HSV keratitis but there are problems with their use and some infections are refractory to treatment. These antivirals also cannot eliminate latent infection and recrudescent infections cause the majority of the blinding keratitis. Strategies that act on virions themselves to prevent attachment or entry into cells are viable strategies that have not been adequately studied. We previously described several peptides that inhibit HSV infection at low micromolar concentrations by inactivating virions in solution, inhibiting entry, and inducing a state of resistance in cells pre-treated with the peptides. These peptides also show little if any toxicity in the eye. Recently, we described a peptide, TAT-C, that inhibits HSV-1 infection and preliminary data suggests TAT-C binds to sialic acids on viral envelope proteins. A second critical finding recently published, is that sialic acids on one or more HSV-1 entry proteins are required for efficient entry into cells. These findings lead us to propose the overall hypothesis that TAT-C inhibits HSV fusion by binding to sialic acids on one or more entry proteins and that this binding interferes with a sialic acid mediated step in the entry process. The experiments in this proposal are designed to test this hypothesis and will be accomplished through four specific aims. 1) Test the hypothesis that TAT-C and sialic acids are involved in an entry step prior to fusion. 2) Test the hypothesis that TAT-C or removal of sialic acids from gB, gD, and/or gH/gL alters the function of the proteins. 3) Test the hypothesis that TAT-C or sialic acid removal alters the structure or stability of gB, gD, and/or gH/gL. 4) Test the hypothesis that sialic acids are critical for in vivo infection and that TAT-C has in vivo efficacy and the effect on latency. These studies will increase our understanding of the role of virion sialic acids in HSV-1 infection and could lead to the development of novel antiviral strategies for therapy.

Public Health Relevance

We describe studies that will determine how sialic acids on HSV-1 envelope glycoproteins affect ocular disease and the role they play in viral entry. We will also test the mechanism whereby a peptide that binds sialic acid blocks HSV-1 infection. The studies will provide new insights into HSV-1 entry and could lead to the development of novel antivirals.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Anterior Eye Disease Study Section (AED)
Program Officer
Mckie, George Ann
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Medicine
United States
Zip Code
Lee, Eun Suk; Rasmussen, Carol A; Filla, Mark S et al. (2014) Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo. Curr Eye Res 39:859-70
Brandt, Curtis R (2014) Peptide therapeutics for treating ocular surface infections. J Ocul Pharmacol Ther 30:691-9
Jose, Gilbert G; Larsen, Inna V; Gauger, Joshua et al. (2013) A cationic peptide, TAT-Cdýý, inhibits herpes simplex virus type 1 ocular infection in vivo. Invest Ophthalmol Vis Sci 54:1070-9
Cardozo, F T G S; Camelini, C M; Cordeiro, M N S et al. (2013) Characterization and cytotoxic activity of sulfated derivatives of polysaccharides from Agaricus brasiliensis. Int J Biol Macromol 57:265-72
Cardozo, F T G S; Larsen, I V; Carballo, E V et al. (2013) In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide. Antimicrob Agents Chemother 57:2541-9
Kolb, Aaron W; Ané, Cécile; Brandt, Curtis R (2013) Using HSV-1 genome phylogenetics to track past human migrations. PLoS One 8:e76267
Larsen, Inna V; Brandt, Curtis R (2010) A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells. J Ocul Pharmacol Ther 26:541-7